On February 21, 2025, according to the resource library, the Dutch biotechnology research company, Oobionics, recently launched Chimera, a biaboporting manufacturing platform incorporating five different technologies.
Chimera incorporates a 3D bioelectric spray, 3D cell electrofilage, a 3D bioelectric liquid jet, an electroelectro-electric electro-electric and 3D cells and standard 3D extrusion biopriting technologies in a system, aimed at simplifying the production process of complex tissue using steel cells, organs, genes and other materials and other materials biological.
Integrated design, simplify complex organizational manufacturing
Traditional bioprome often requires several devices to perform different technical steps, and Chimera allows researchers to finish several biaboporting tasks on a single platform thanks to an integrated design. This integration not only improves efficiency, but also provides more flexible tools for researchers in fields such as tissue engineering, regenerative medicine and synthetic biology.
Ourobionics Chimera Platform. Ourobionics photos
“The Chimera platform is a cutting-edge tool for scientists, industry and health professionals in tissue engineering, regenerative medicine, synthetic biology and cellular products, and it will revolutionize the way in which these areas are studied,” said Dr. Ali Shooshtari, director of ourobionics technology.
High cell survival rate and rapid manufacturing capacity
One of the main advantages of the chimera is its high cell survival rate. The platform would have reached up to 98% cell survival in 56 types of cells, including stem cells and even intact embryos. In addition, its manufacturing speed is far beyond traditional extrusion bioprimimination technology, and it can create a structure of 1 cube centimeter in about a minute, which is 30 times faster than the traditional method.
The characteristic photographs show (a) the control embryos and (b) the pulverized embryos at the post-retaliation period of 48 hours. Image of Ourobionics
At the same time, the platform also has a nanometric scale resolution (up to 50 nanometers), which can create very fine scaffolding and tissue structures. Its encapsulation technology can treat cells, cell grapes, genes and gene clusters, further expanding its range of applications in cell therapy, synthetic biology and bioprating.
Large applicability and technical background
The platform supports a variety of biomaterials, including different viscosity materials, offering researchers greater flexibility. By reducing the pressure on cells by extrusion technology, the chimera effectively solves the problems of cell protection and metabolic integrity in biopritation.
Chimera’s bioelectric manufacturing technology comes from the results of Professor Suwan Jayasinghe, founder and scientific director of Ourobionics at the University College London (UCL). The founders of Ourobionics, Dr. Stephen G. Gray and Dr Ali Shooshtari, on this basis, combined with the research experience of the Imperial College and were still optimized.
Currently, more than 150 scientific publications have detailed the capacity of the platform to manufacture complex tissue structures while protecting cellular functions.
Promote the development of medicine for bio-fabrication and regeneration
As early as 2024, the development of Chimera was supported by the venture capital led by OOSTNL and the HIGHTECH NXTGEN HIGHTECH program. This financial support makes Chimera a key tool in the promotion of research in biopingation and regeneration medicine.
Ourobionics said that Chimera is suitable not only for university research, but that it also meets the needs of industry. For researchers and companies that require complex tissue engineering and biomaterial development, Chimera offers a more efficient and practical solution.
Latest progress in the field of bio-fabrication
Research in the field of bioprometer has made significant progress in recent years. In February 2024, a research team from Carnegie Mellon University (CMU) developed an ICE 3D printing technology to create complex structures similar to blood vessels. Technology has successfully supported the growth of endothelial cells of two weeks using heavy water printing ice models and hardening of gelatin materials through ultraviolet rays, showing potential in organ transplantation, drug screening tests and personalized medicine.
On the left is a model of vascular ice printed in 3D. On the right side is an image of cells forming vascular structures on the model a week later. CMU photos
In addition, scientists from the University of Sydney and the Institute of Children’s Medicine (IRM) have developed a 3D photolithography method which can create human tissues very similar to the real organ structure. The technology guides stem cells to differentiate in specific cells by precise mechanical and chemical signals, successfully built the assembly of bone fat and reproduces the first processes of mammal development. This technology has large prospects for applying for regenerative medicine, disease modeling and cell therapy.
Possibility of demand
The launch of Chimera marks an important step towards higher integration and higher efficiency in bio-fabrication technologies. With the continuous development of bio-fabrication technology, functional tissues should be cultivated in laboratories in the future, providing revolutionary breakthroughs in organ transplantation, disease treatment and personalized medicine.
On Ourobionics
Ourobionics is a Dutch company focused on the research and development of biopingation technologies, committed to promoting the development of tissue engineering, regenerative medicine and synthetic biology thanks to innovative technologies. The launch of the Chimera platform also consolidates its main position in the field of bio-fabrication.
